RELMADA THERAPEUTICS INC's ticker is RLMD and the CUSIP is 75955J402. A total of 118 filers reported holding RELMADA THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is 0.57 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $3,930,105 | +22.0% | 1,310,035 | 0.0% | 0.00% | – |
Q2 2023 | $3,222,686 | -5.3% | 1,310,035 | -13.0% | 0.00% | – |
Q1 2023 | $3,401,253 | -35.8% | 1,504,979 | -0.8% | 0.00% | – |
Q4 2022 | $5,294,260 | -90.1% | 1,516,980 | +5.1% | 0.00% | -100.0% |
Q3 2022 | $53,456,000 | +97.8% | 1,443,960 | +1.5% | 0.00% | +100.0% |
Q2 2022 | $27,023,000 | -24.4% | 1,423,032 | +7.5% | 0.00% | 0.0% |
Q1 2022 | $35,736,000 | +29.5% | 1,324,014 | +8.1% | 0.00% | 0.0% |
Q4 2021 | $27,598,000 | +15.1% | 1,224,901 | +33.9% | 0.00% | 0.0% |
Q3 2021 | $23,975,000 | -3.0% | 914,723 | +18.5% | 0.00% | 0.0% |
Q2 2021 | $24,705,000 | +1.2% | 771,776 | +11.3% | 0.00% | 0.0% |
Q1 2021 | $24,411,000 | +14.9% | 693,307 | +4.6% | 0.00% | 0.0% |
Q4 2020 | $21,250,000 | -16.0% | 662,623 | -1.5% | 0.00% | 0.0% |
Q3 2020 | $25,311,000 | -18.2% | 672,781 | -2.7% | 0.00% | 0.0% |
Q2 2020 | $30,951,000 | +56.5% | 691,652 | +19.3% | 0.00% | 0.0% |
Q1 2020 | $19,779,000 | -11.0% | 579,858 | +1.8% | 0.00% | 0.0% |
Q4 2019 | $22,220,000 | – | 569,753 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
VR Adviser, LLC | 853,206 | $30,041,000 | 3.26% |
COMMODORE CAPITAL LP | 161,565 | $5,689,000 | 2.27% |
TANG CAPITAL MANAGEMENT LLC | 200,000 | $7,042,000 | 1.98% |
PARSONS CAPITAL MANAGEMENT INC/RI | 451,412 | $15,894,000 | 1.30% |
Avoro Capital Advisors LLC | 1,525,000 | $53,695,000 | 0.93% |
RTW INVESTMENTS, LP | 1,530,717 | $53,897,000 | 0.84% |
Pegasus Asset Management, Inc. | 26,958 | $949,000 | 0.48% |
COWEN AND COMPANY, LLC | 166,942 | $5,878,000 | 0.40% |
Ikarian Capital, LLC | 290,207 | $10,218,000 | 0.34% |
Spotlight Asset Group, Inc. | 24,565 | $865,000 | 0.32% |